1. Mycophenolate mofetil after tacrolimus for refractory clinically amyopathic dermatomyositis: a case report
- Author
-
Gui-Chen Ling, Chang Su, Ying-Ao Guo, Xia Qiu, Jia-Wei Liu, Min Xiao, Yu-Ya Xiao, Shuo Yang, Jian-Yong Zhang, and Jing-Jing Xie
- Subjects
anti-MDA5-associated dermatomyositis ,case report ,rapidly progressive interstitial lung disease ,mycophenolate mofetil ,clinically amyopathic dermatomyositis (CADM) ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Dermatomyositis (DM) positive for anti-melanoma differentiation-associated gene 5 (MDA5) antibodies, mainly when linked with rapidly progressive interstitial lung disease (RP-ILD), is considered a refractory disease. Our report describes a critical case of clinically amyopathic dermatomyositis (CADM) with RP-ILD that tested positive for both anti-MDA5 and anti-Ro-52 antibodies. The patient showed a limited response to a combined therapy regimen of prednisone, iguratimod, and tacrolimus. However, after adjunct therapy with mycophenolate mofetil (MMF), the patient’s condition was controlled, his serum KL-6 levels decreased, and anti-MDA5 antibodies became negative. During the 68-week follow-up, the patient’s condition remained stable, with a satisfactory quality of life. This report also discusses the potential role of inflammatory cytokines in the pathophysiology of CADM and RP-ILD. Further research is required to confirm these results and investigate the application of MMF in maintenance therapy for CADM-associated RP-ILD.
- Published
- 2024
- Full Text
- View/download PDF